Keenova Q3 2026: Net Sales Up, Losses Shrink
A Strong Quarter Despite Some Knocks It ain't every day you see a company like Keenova Therapeutics clocking solid top-line growth, despite battling the waves of operational losses. Now, don't get me wrong; I ain't swooning over their near $96 million loss from continuing operations, but let me give credit where it's due—those sales numbers popped impressive. Pillars of...
Continue Reading